Home

Provides new pathways for biomarkers and drug discovery for cancer patients.  Background:
The gene Abelson interactor protein-1 (ABI1) encodes a member of the Abelson-interactor family of adaptor proteins. These proteins facilitate signal transduction as components of several multiprotein complexes, and regulate actin polymerization and cytoskeletal remodeling through interactions with Abelson tyrosine kinases. The androgen receptor (AR) protein functions as a steroid-hormone activated transcription factor. ABI1 and AR are widely expressed in human tissues. Many cancers show sex-specific tumorigenesis, tumor progression, and sensitivity to hormonal drugs. The ABI1-AR axis might play critical roles in these tissue and drug sensitivities and toxicities. For example, ABI1 regulates a specific subset of genes associated with prostate tumor progression. These genes are biomarkers and potential targets of tumor progression.
Technology Overview:  
This technology defines ABI1-AR reciprocal regulation involving two non-exclusive molecular mechanisms of ABI1-AR and ABI1-DNA interactions. ABI1-DNA binding activity predicts survival of prostate cancer patients. ABI1 binds AR via a multivalent interaction. The ABI1-AR transcriptional program is altered during tumor progression and by anti-androgen treatments, suggesting that ABI1 is a key plasticity regulator in PCa by coupling its actin regulatory and signaling functions to transcriptional regulation. ABI1-AR reciprocal regulation has far reaching implications for tumor plasticity and androgen-sensitive pathogenesis. These interactions are co-regulated during PCa evolution and clinical treatment promoting tumor plasticity and progression. This provides new paths for biomarker and drug design discovery in PCa. https://suny.technologypublisher.com/files/sites/adobestock_282277912.jpegAdvantages:  
•    Provides a novel mechanism for predicting survival rates among cancer patients.
•    May enable drug discovery for a wide variety of cancers. Applications:  
The primary applications for this technology are the development of biomarkers for assessing cancer patient survival rates, and drug discovery.  Intellectual Property Summary: US Provisional Patent Application Ser. No. 63/463,457, filed May 2, 2023. Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of biomarkers and/or therapeutics for cancer, including:
•    Pharmaceutical companies.
•    Hospitals.
•    Medical research laboratories.
•    Universities.

 

A novel approach to the development of new and effective cancer treatment options.  Background:
The Mixed Lineage Leukemia 1 (MLL1) protein is a member of the SET1 family of proteins. Mutations of the MLL1 core complex leads to excessive di- and trimethylation of H3K4 which alters gene regulation. This has been linked to certain types of leukemia, solid tumors, and psychotropic disorders such as schizophrenia and bipolar disorders. The minimal complex required for di- and trimethylation of H3K4 includes MLL1 or SETd1a, WDR5, RbBP5, Ash2L and DPY-30. The protein WDR5 bridges the catalytic SET domain of SET1 family proteins and the regulatory components of RbBP5 and Ash2L. Currently, there are no approaches for inhibiting the formation of SET1 family core complexes for the treatment of leukemia and other disorders.Technology Overview:  
This technology from Upstate Medical University provides peptide-based inhibitors of the SET1 family core complexes. These peptides can be used to inhibit the growth of cancer cells. These peptide inhibitors can inhibit the enzymatic activity of complexes of MLL1 and SETd1A. The peptide inhibitors may act by inhibiting the formation of, or by disrupting, MLL1 and SETd1A complexes. The peptide inhibitors may also enhance the activity of MLL3, which is a known tumor suppressor. The administration of a compound based on this approach can be used alone or combined with chemotherapy, radiation therapy, surgical removal of tumors, or combinations thereof, and/or with a diagnostic technique. https://suny.technologypublisher.com/files/sites/adobestock_2229417291.jpeg Advantages:  
This technology provides a new approach for the development of compounds that could treat various forms of cancer. It may also be used for the development of treatments for psychotropic disorders.  Applications:  
The primary application for this technology is cancer treatment. It may also be used for the treatment of psychotropic disorders such as schizophrenia and bipolar disorders.
 Intellectual Property Summary:
This technology is covered by the patent US 10392423 B2, “Peptide-Based Inhibitors of MLL / SET1 Family Core Complexes.”
https://patents.google.com/patent/US10392423B2/ Stage of Development:
TRL 3 - Experimental proof of concept
Licensing Status This technology is available for licensing. Licensing Potential
This technology will be of value to any company or institution involved in treating cancer. This includes:
•    Pharmaceutical companies
•    Hospitals 
•    Research centers

We anticipate that this topical treatment will increase genital sensitivity in women, facilitating sexual arousal and helping treat sexual dysfunction. Background:
As the population ages, there has been increased focus around sexual dysfunction as a medical issue. This has resulted in a number of successful treatments that ameliorate sexual dysfunction in men. However, treatments aimed at woman have not been nearly as effective. One of the reasons for this is that female sexual dysfunction is complex. At least one likely factor contributing to female dysfunction is diminished genital sensitivity arising from loss of sensory nerve fibers in the clitoris and vagina.Technology Overview:  
This technology is based on the hypothesis that topical 4-aminopyridine (4-AP) may enhance the sensitivity of the sensory nerves in the genital region and increase female sexual arousal. This medication has already been approved for oral use to improve neuronal function in conditions where either peripheral nerves or central neurons have impaired transmitter release or defective axonal conduction. We believe that 4-AP’s ability to prolong action potentials and facilitate the repetitive firing of neurons will allow it to be used topically as a treatment for sexual dysfunction. https://suny.technologypublisher.com/files/sites/adobestock_5878419381.jpegAdvantages:  
•    Easy and safe topical application
•    Uses medication that has already been approved for a different purpose. Applications:  
The primary use for this technology is for treatment of female sexual dysfunction. Intellectual Property Summary:
Patent Issued: US10888552B2, “Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability” (see also https://patents.google.com/patent/US10888552B2/en). Stage of Development:
TRL 2, Technology concept and/or application formulated.Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the treatment of female sexual dysfunction, including:
•    Pharmaceutical companies.
•    Hospitals.
•    Health care providers.
•    Medical research laboratories.

­A method for improving fluid flow around or through an endoscope using radially oriented projections. Background:
During ureteroscopy, the irrigation fluid used to distend the kidney and make stones easier to extract can also cause problems. It can cause a buildup of pressure in the pelvis, and any bacteria which are present can get pushed up into the kidney with the fluid, placing patients at risk for sepsis and pain.Intrapelvic pressure is directly related to fluid inflow and outflow. Mathematical models examining fluid flow patterns within the pelvis and ureter during ureteroscopy suggest that the diameter of the endoscope is a critical parameter in fluid flow rate. Lower pressure is thought to reduce bleeding and sepsis.
Technology Overview: 
SUNY Upstate Medical University researchers have determined the optimal shape of a ureteroscope for reducing intrapelvic pressure. They found that by offsetting the endoscope to the side of the access sheath, fluid outflow was improved and pressure was reduced. In order to achieve this displacement in a stable way, they added small, radially emanating, collapsible projections either to the inside the ureteral access sheath or to the shaft of the ureteroscope itself. Any endoscope or catheter can be adapted with these projections, including bronchoscopes. https://suny.technologypublisher.com/files/sites/adobestock_337037079_(1).jpegAdvantages: 
 
•    Reduces pressure that can cause infection, injury, and pain.
•    Modifications can be used to adapt any endoscope or catheter. Applications: 
 
•    Reduces pressure buildup during endoscopic procedures.  Intellectual Property Summary:

•    Provisional Filed 63/150,163
Licensing Status:
This technology is available for licensing.